Oxaliplatin and infliximab synergize to induce regression of colon cancer

Huang,Di; Xue,Jun; Li,Shuguang; Yang,Dongdong

doi:10.3892/ol.2017.7468

Oxaliplatin and infliximab synergize to induce regression of colon cancer

Authors:
- Di Huang
- Jun Xue
- Shuguang Li
- Dongdong Yang
View Affiliations

Affiliations: Department of Gastrointestinal Surgical Oncology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei 075000, P.R. China, Department of Vascular and Gland Surgery, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei 075000, P.R. China
Published online on: November 22, 2017 https://doi.org/10.3892/ol.2017.7468
Pages: 1517-1522
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

There is currently a lack of therapeutic options for patients with advanced colon cancer. Although certain chemotherapies are able to suppress the progression slightly, the response rate is low, and side effects of treatment and tumor recurrence continue to present problems for clinicians. Tumor necrosis factor‑α (TNF‑α) has been identified to possess tumor‑promoting properties. In the present study, the effect of anti‑TNF‑α treatment (infliximab) in combination with chemotherapy on colon cancer was investigated. Tumor tissue samples were collected from patients with colon cancer who received oxaliplatin (OXA) treatment. Their TNF‑α expression levels were examined with regard to their sensitivity to OXA. OXA‑resistant colon cancer cell lines were established to explore the effects of anti‑TNF‑α treatment and OXA treatment. Furthermore, an OXA‑resistant colon cancer xenograft mouse model was created and the effects of the combination treatment of anti‑TNF‑α and OXA on the mice were assessed. The results of the present study indicated that TNF‑α was increased in the tumor tissue of patients with colon cancer who were resistant to OXA and also in OXA‑resistant colon cancer cell lines. Anti‑TNF‑α treatment using infliximab inhibited the survival of OXA‑resistant colon cancer cell lines by inducing antibody‑dependent cellular cytotoxicity and complement‑dependent cytotoxicity effects. The combination of infliximab and OXA treatment achieved increased efficacy on the OXA‑resistant colon cancer xenograft mouse model compared with treatment with OXA alone. On the basis of the results of the present study, it was concluded that infliximab may sensitize colon cancer cells to OXA treatment.

View Figures

View References

1	Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin. 56:106–130. 2006. View Article : Google Scholar : PubMed/NCBI
2	Jonker DJ, Maroun JA and Kocha W: Survival benefit of chemotherapy in metastatic colorectal cancer: A meta-analysis of randomized controlled trials. Br J Cancer. 82:1789–1794. 2000. View Article : Google Scholar : PubMed/NCBI
3	Kohne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, et al: Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: Results of a multivariate analysis of 3825 patients. Ann Oncol. 13:308–317. 2002. View Article : Google Scholar : PubMed/NCBI
4	André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 350:2343–2351. 2004. View Article : Google Scholar : PubMed/NCBI
5	Eisenman ST, Gibbons SJ, Verhulst PJ, Cipriani G, Saur D and Farrugia G: Tumor necrosis factor alpha derived from classically activated ‘M1’ macrophages reduces interstitial cell of Cajal numbers. Neurogastroenterol Motil. 29:2017. View Article : Google Scholar : PubMed/NCBI
6	Mocellin S, Rossi CR, Pilati P and Nitti D: Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev. 16:35–53. 2005. View Article : Google Scholar : PubMed/NCBI
7	van Horssen R, Ten Hagen TL and Eggermont AM: TNF-alpha in cancer treatment: Molecular insights, antitumor effects, and clinical utility. Oncologist. 11:397–408. 2006. View Article : Google Scholar : PubMed/NCBI
8	Wu Y and Zhou BP: TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. Br J Cancer. 102:639–644. 2010. View Article : Google Scholar : PubMed/NCBI
9	Chen G and Goeddel DV: TNF-R1 signaling: A beautiful pathway. Science. 296:1634–1635. 2002. View Article : Google Scholar : PubMed/NCBI
10	Sedger LM and McDermott MF: TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants-past, present and future. Cytokine Growth Factor Rev. 25:453–472. 2014. View Article : Google Scholar : PubMed/NCBI
11	Stuelten CH, DaCosta Byfield S, Arany PR, Karpova TS, Stetler-Stevenson WG and Roberts AB: Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-alpha and TGF-beta. J Cell Sci. 118:2143–2153. 2005. View Article : Google Scholar : PubMed/NCBI
12	Harrison ML, Obermueller E, Maisey NR, Hoare S, Edmonds K, Li NF, Chao D, Hall K, Lee C, Timotheadou E, et al: Tumor necrosis factor alpha as a new target for renal cell carcinoma: Two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol. 25:4542–4549. 2007. View Article : Google Scholar : PubMed/NCBI
13	Ohri CM, Shikotra A, Green RH, Waller DA and Bradding P: Tumour necrosis factor-alpha expression in tumour islets confers a survival advantage in non-small cell lung cancer. BMC Cancer. 10:3232010. View Article : Google Scholar : PubMed/NCBI
14	Sethi G, Sung B and Aggarwal BB: TNF: A master switch for inflammation to cancer. Front Biosci. 13:5094–5107. 2008. View Article : Google Scholar : PubMed/NCBI
15	Terzic J, Grivennikov S, Karin E and Karin M: Inflammation and colon cancer. Gastroenterology. 138:2101–2114.e5. 2010. View Article : Google Scholar : PubMed/NCBI
16	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
17	Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, et al: Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA. 104:pp. 3360–3365. 2007; View Article : Google Scholar : PubMed/NCBI
18	Ray A and Dittel BN: Isolation of mouse peritoneal cavity cells. J Vis Exp. pii:14882010.
19	Rossi CR, Foletto M, Pilati P, Mocellin S and Lise M: Isolated limb perfusion in locally advanced cutaneous melanoma. Semin Oncol. 29:400–409. 2002. View Article : Google Scholar : PubMed/NCBI
20	Christoforidis D, Martinet O, Lejeune FJ and Mosimann F: Isolated liver perfusion for non-resectable liver tumours: A review. Eur J Surg Oncol. 28:875–890. 2002. View Article : Google Scholar : PubMed/NCBI
21	Orosz P, Echtenacher B, Falk W, Rüschoff J, Weber D and Männel DN: Enhancement of experimental metastasis by tumor necrosis factor. J Exp Med. 177:1391–1398. 1993. View Article : Google Scholar : PubMed/NCBI
22	Suganuma M, Okabe S, Marino MW, Sakai A, Sueoka E and Fujiki H: Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res. 59:4516–4518. 1999.PubMed/NCBI
23	Tsimberidou AM, Waddelow T, Kantarjian HM, Albitar M and Giles FJ: Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR: Fc; Enbrel) in patients with refractory multiple myeloma: Increase in plasma TNF alpha levels during treatment. Leuk Res. 27:375–380. 2003. View Article : Google Scholar : PubMed/NCBI
24	Giordano M, Roncagalli R, Bourdely P, Chasson L, Buferne M, Yamasaki S, Beyaert R, van Loo G, Auphan-Anezin N, Schmitt-Verhulst AM and Verdeil G: The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells. Proc Natl Acad Sci USA. 111:pp. 11115–11120. 2014; View Article : Google Scholar : PubMed/NCBI